Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

lisdexamfetamine dimesylate

Shire Basingstoke

Shire completes $32bn Baxalta merger

Creates world leading rare diseases specialist

- PMLiVE

Shire launches digital ‘paper planes’ for rare disease campaign

#FlyForMPS allows supporters to track the miles their plane travels

- PMLiVE

First online ADHD treatment test launched in the US

Qbtech brings its QbCheck assessment to market after winning FDA approval

Shire Basingstoke

Shire says Baxalta merger on track despite US tax clampdown

After Pfizer/Allergan deal falls apart company says its combination will still go ahead

Shire Basingstoke

Shire launches long-acting ADHD drug Intuniv in UK

Also plans to launch the once-daily treatment in Japan later this year

- PMLiVE

Challenging perceptions

Alvaro Herreros on the ADHD landscape

- PMLiVE

Alkermes depression drug misses targets in phase III

Irish firm suffers major research setback with ALKS 5461

- PMLiVE

Baxalta agrees to $32bn Shire takeover

Deal will  create one of the industry's top rare disease firms

Shire Basingstoke

Shire deal with Baxalta predicted this week

Takeover talks reported to be at an advanced stage

Shire Basingstoke

FDA grants fast track designation to Shire’s Cinryze

Kidney transplant treatment in line for regulatory assistance

- PMLiVE

FDA deals a big blow to Shire’s late-stage pipeline

Additional data required before firm can apply for re-approval

- PMLiVE

Shire picks winner for Gaucher film contest

Argentinianfilm My Daughter takes home the competition's top prize

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links